Biological Activity
CNQX is a potent AMPA/kainate receptor antagonist. Also antagonist at glycine modulatory site on NMDA receptor complex.
In Vitro
CNQX disodium (FG9065 disodium; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices[2]. CNQX disodium (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments[3].
In Vivo
CNQX disodium (FG9065 disodium; 0.75-3 mg/kg; IP; 20 min before testing) decreased the number of cocaine responses in a dose-dependent manner during the first 15-min cocaine-free interval[4]. The bilateral infusion of CNQX disodium (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX disodium causes a complete blockade at a dose of 0.5 μg[5]. Animal Model: Male Wistar rats weighing 180-200 g[4] Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval.
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
